Company intelligence / Profile preview

Prosite Biotechnology

Baltimore, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Initiated first-in-human Phase I clinical trial of PSP001 (PEGIFN-λ Chimera) in the US in May 2021; lead candidates include PEGINF-λ chimeric pursuing IND and FGF-18 chimeric in pre-clinical.

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Recombinant fusion protein
Industry: Biotech

Drug pipeline

1 asset

PSP001

Unknown

Beyond the preview

Go deeper on Prosite Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prosite Biotechnology.

Explore the full profile